Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 6/2015

01-06-2015 | Current Opinion

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease

Authors: Daphne Robakis, Stanley Fahn

Published in: CNS Drugs | Issue 6/2015

Login to get access

Abstract

Inhibitors of monoamine oxidase-B (MAO-B) occupy an important place in the treatment of Parkinson’s disease. Selegiline was the first MAO-B to be used therapeutically, while rasagiline is a second-generation drug with higher potency and selectivity. Safinamide is an investigational MAO-B inhibitor with non-dopaminergic properties that may provide advantages over its predecessors. As a class, MAO-B inhibitors are safe and well tolerated and provide symptomatic benefit both as monotherapy and in combination with other antiparkinsonian medications from early to late stages of disease. In combination with levodopa, MAO-B inhibitors may improve motor fluctuations and allow for lower total doses of levodopa. Patient characteristics and preferences can be important factors in deciding between agents. As a class, MAO-B inhibitors have shown promise as disease-modifying agents, but the clinical trial evidence to date has not been strong enough to afford them such a label. Future research may help further elucidate their relative merits and clarify their role in altering disease progression.
Literature
1.
2.
Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968;17(7):1285–97.PubMedCrossRef
3.
Kalgutkar AS, Dalvie DK, Castagnoli N Jr, Taylor TJ. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol. 2001;14(9):1139–62.PubMedCrossRef
4.
Saura Marti J, Kettler R, Da Prada M, Richards JG. Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm Suppl. 1990;32:49–53.
5.
Kaakkola S, Mannisto PT, Nissinen E. Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat. J Neural Transm. 1987;69(3–4):221–8.PubMedCrossRef
6.
Berry MD, Scarr E, Zhu MY, Paterson IA, Juorio AV. The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine. Br J Pharmacol. 1994;113(4):1159–66.PubMedCentralPubMedCrossRef
7.
Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy. 2007;27(12 Pt 2):174s–85s.PubMedCrossRef
8.
9.
10.
Stowe R, Ives N, Clarke CE, Handley K, Furmston A, Deane K, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson’s disease. Mov Disord. 2011;26(4):587–98.PubMedCrossRef
11.
Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson’s disease. Cochrane Database Syst Rev. 2009(4):Cd006661.
12.
Zagmutt FJ, Tarrants ML. Indirect comparisons of adverse events and dropout rates in early Parkinson’s disease trials of pramipexole, ropinirole, and rasagiline. Int J Neurosci. 2012;122(7):345–53.PubMedCrossRef
13.
Stacy M. Medical treatment of Parkinson disease. Neurol Clin. 2009;27(3):605–31, v.
14.
Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord. 2015 Jan;30(1):4-18.
15.
16.
Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22(10):1379–89 (quiz 523).
17.
Asanuma M, Miyazaki I, Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res. 2003;5(3):165–76.PubMedCrossRef
18.
19.
Perry TL, Yong VW, Ito M, Foulks JG, Wall RA, Godin DV, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of l-DOPA and carbidopa chronically. J Neurochem. 1984;43(4):990–3.PubMedCrossRef
20.
Parkkinen L, O’Sullivan SS, Kuoppamaki M, Collins C, Kallis C, Holton JL, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology. 2011;77(15):1420–6.PubMedCrossRef
21.
Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol. 1998;43(5):561–75.PubMedCrossRef
22.
Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol. 2005;252 Suppl 4:Iv37–42.
23.
Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731–42.PubMedCentralPubMedCrossRef
24.
Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–71.CrossRef
25.
Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7 Suppl 2):S18–23.PubMedCrossRef
26.
Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science (New York, NY). 1989;245(4917):519–22.
27.
28.
Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm. 2003;110(5):509–15.PubMedCrossRef
29.
Wu RM, Chen RC, Chiueh CC. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann N Y Acad Sci. 2000;899:255–61.PubMedCrossRef
30.
Kumar MJ, Andersen JK. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol Neurobiol. 2004;30(1):77–89.PubMedCrossRef
31.
Kandadai RM, Jabeen SA, Kanikannan MA, Borgohain R. Safinamide for the treatment of Parkinson’s disease. Expert Rev Clin Pharmacol. 2014;7(6):747–59.PubMedCrossRef
32.
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361(13):1268–78.PubMedCrossRef
33.
Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12(8):747–55.PubMedCentralPubMedCrossRef
34.
Finberg JP. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014;143(2):133–52.PubMedCrossRef
35.
Finberg JP, Tenne M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol. 1982;77(1):13–21.PubMedCentralPubMedCrossRef
36.
Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989;46(1):45–50.PubMedCrossRef
37.
Chen JJ, Wilkinson JR. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? J Clin Pharmacol. 2012;52(5):620–8.PubMedCrossRef
38.
deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, et al. Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21(10):1716–21.
39.
Goren T, Adar L, Sasson N, Weiss YM. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol. 2010;50(12):1420–8.PubMedCrossRef
40.
McCormack PL. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. CNS Drugs. 2014;28(11):1083–97.PubMedCrossRef
41.
Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014;34(12):1250–8.PubMedCrossRef
42.
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241–8.CrossRef
43.
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183–9 (quiz 313).
44.
Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229–36.PubMedCentralPubMedCrossRef
45.
Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;16(3):178–83.PubMedCrossRef
46.
Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408.PubMed
47.
Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm. 1985;64(2):113–27.PubMedCrossRef
48.
Gerlach M, Youdim MB, Riederer P. Pharmacology of selegiline. Neurology. 1996;47(6 Suppl 3):S137–45.PubMedCrossRef
49.
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328(3):176–83.CrossRef
50.
Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. ement disorders. Mov Disord. 1993;8(Suppl 1):S36–40.PubMedCrossRef
51.
Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology. 1992;42(2):339–43.PubMedCrossRef
52.
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51(5):604–12.PubMedCrossRef
53.
Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson’s disease? Results from a five-year study. The Norwegian–Danish Study Group. Eur J Neurol. 1999;6(5):539–47.
54.
Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66(8):1200–6.PubMedCrossRef
55.
Przuntek H, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6(2):141–50.PubMedCrossRef
56.
Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol. 1995;38(5):771–7.PubMedCrossRef
57.
Stocchi F, Olanow CW. Neuroprotection in Parkinson’s disease: clinical trials. Ann Neurol. 2003;53 Suppl 3:S87–97 (discussion S-9).
58.
Riederer P, Lachenmayer L. Selegiline’s neuroprotective capacity revisited. J Neural Transm. 2003;110(11):1273–8.PubMedCrossRef
59.
Zhao YJ, Wee HL, Au WL, Seah SH, Luo N, Li SC, et al. Selegiline use is associated with a slower progression in early Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times. Parkinsonism Relat Disord. 2011;17(3):194–7.PubMedCrossRef
60.
Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson’s disease. Drug Safety. 1998;19(1):11–22.PubMedCrossRef
61.
Karlsen K, Larsen JP, Tandberg E, Jørgensen K. Fatigue in patients with Parkinson’s disease. Mov Disord. 1999;14(2):237–41.PubMedCrossRef
62.
Stocchi F, Abbruzzese G, Ceravolo R, Cortelli P, D’Amelio M, De Pandis MF, et al. Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology. 2014;83(3):215–20.PubMedCrossRef
63.
Finberg JP, Youdim MB. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002;43(7):1110–8.PubMedCrossRef
64.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937–43.CrossRef
65.
Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947–54.PubMedCrossRef
66.
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561–6.CrossRef
67.
Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov Disord. 2009;24(4):564–73.PubMedCrossRef
68.
Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415–23.PubMedCrossRef
69.
Cattaneo C, Caccia C, Marzo A, Maj R, Fariello RG. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol. 2003;26(4):213–7.PubMedCrossRef
70.
Chazot PL. Safinamide for the treatment of Parkinson’s disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs. 2007;8(7):570–9.
71.
Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord. 2012;27(1):106–12.PubMedCrossRef
72.
Barone P, Fernandez H, Ferreira J, Mueller T, Saint-Hilaire M, Stacy M, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). Neurology. 2013;80:Meeting abstracts 1 P01.061.
73.
Schapira AH, Fox S, Hauser R, Jankovic J, Jost W, Kulisevsky J, et al. Safinamide add on to L-dopa: a randomized, placebo-controlled 24-week global trial in patients with Parkinson’s disease and motor fluctuations (SETTLE). Neurology. 2013;80:Meeting Abstracts 1 P01.062.
74.
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–37.PubMedCrossRef
75.
Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19(5):508–14.PubMedCrossRef
76.
Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, et al. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PloS One. 2010;5(12):e15298.PubMedCentralPubMedCrossRef
77.
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014 Sep;29(10):1273-80.
78.
Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330(9):613–22.PubMedCrossRef
79.
Vaarmann A, Kovac S, Holmstrom KM, Gandhi S, Abramov AY. Dopamine protects neurons against glutamate-induced excitotoxicity. Cell Death Dis. 2013;4:e455.PubMedCentralPubMedCrossRef
80.
Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63(4):746–8.PubMedCrossRef
81.
Stocchi F, Vacca L, Grassini P, De Pandis MF, Battaglia G, Cattaneo C, et al. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. 2006;67(7 Suppl 2):S24–9.PubMedCrossRef
82.
Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord. 2014;29(8):1028–34.PubMedCrossRef
83.
Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol. 2013;20(2):271–80.PubMedCrossRef
84.
Marconi S, Zwingers T. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2014;18(13):1879–82.PubMed
85.
Jost WH, Friede M, Schnitker J. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2014;18(22):3349.PubMed
86.
Jost WH, Friede M, Schnitker J. Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease. Basal Ganglia. 2012;2(4, Supplement):S17–26.
87.
Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol. 2011;10(8):734–44.PubMedCrossRef
88.
89.
Schapira AH, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann Neurol. 2006;59(3):559–62.PubMedCrossRef
90.
91.
Knudsen Gerber DS. Selegiline and rasagiline: twins or distant cousins? Consult Pharm. 2011;26(1):48–51.PubMedCrossRef
92.
Miklya I. Essential difference between the pharmacological spectrum of (−)-deprenyl and rasagiline. Pharmacol Rep. 2014;66(3):453–8.PubMedCrossRef
93.
Robottom BJ. Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease. Patient Prefer Adher. 2011;5:57–64.CrossRef
Metadata
Title
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease
Authors
Daphne Robakis
Stanley Fahn
Publication date
01-06-2015
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 6/2015
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-015-0249-8

Other articles of this Issue 6/2015

CNS Drugs 6/2015 Go to the issue

Original Research Article

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

Adis Drug Evaluation

Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome

Review Article

Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations

Review Article

Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

Leading Article

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date

Current Opinion

Targeting CGRP: A New Era for Migraine Treatment